Fujifilm set to invest $928m into ex-Biogen facility

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Ghing)
(Image: Getty/Ghing)

Related tags: Fujifilm diosynth biotechnologies, Denmark, bioreactor

The company will have sunk nearly $2bn into the facility, after acquiring and planning to double its capacity.

Fujifilm Diosynth Biotechnologies’ decision to purchase Biogen’s biologics facility​ signaled its intention to become a major contract development and manufacturing organization (CDMO) industry player, after spending $890m (€786m) to acquire the site.

Fujifilm has now underlined its ambitions by announcing an approximate $928m expansion project at the same location.

The company wants to double the Danish site’s current drug substance manufacturing capacity, as well as expanding its capabilities in fill/finish, and to make improvements to its assembly, labeling and packaging services.

After the project is complete, the facility will become of the ‘few major large-scale manufacturing facilities’ in the bio-CDMO industry, the company stated.

The plan is to add an additional six 20,000L mammalian cell bioreactors, which would see the facility house 12 bioreactors and increase overall capacity to 240,000L, by the fall of 2023.

Prior to this, a new packaging line will be added in spring 2022, and a new fill/finish production line by summer 2023.

According to Takatoshi Ishikawa, general manager of bio-CDMO division at Fujifilm, the rapid growth and high capital investment has been driven by orders placed by customers. Partly, this has been down to capacity reservation made by the COVID-19 Therapeutics Accelerator​.

Further than this, Martin Meeson, CEO of Fujifilm Diosynth, stated that the investment would allow the CDMO to scale production volumes to manage both small and large batches – enabling the company to work with partners from pre-clinical through to commercialization.

However, the company did reveal that it may take some time for it recoup its investment at the site. Fujifilm Diosynth plans to manage sales of ¥100bn ($928m) by the fiscal year ending March 2022 and expects to exceed ¥200bn in sales by March 2026.

At present, Fujifilm Diosynth is focusing on expansion, leading to the creation of a research center​ earlier this year in the UK, and also investing in its gene therapy capabilities​ at its site in the US.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more